(Q34189149)

31 July 2017

1 reference

title

Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

Michel ML

1

1 reference

31 July 2017

Pol S

series ordinal

2

1 reference

31 July 2017

Brechot C

series ordinal

3

1 reference

31 July 2017

Tiollais P

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

17-19

1 reference

31 July 2017

page(s)

2395-2399

1 reference

Hepatitis B virus infection

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

New therapies for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

1 reference

7 January 2021

Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Specific vaccine therapy in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

DNA-based immunization against the envelope proteins of the hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Muscle-specific expression of hepatitis B surface antigen: no effect on DNA-raised immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900461-8

7 January 2021

10.1016/S0264-410X(00)00461-8

Identifiers

DOI

1 reference

31 July 2017

1 reference